14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $3.81 $4.81 Thursday, 2nd May 2024 NVAX stock ended at $4.71. This is 0.86% more than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 3.80% from a day low at $4.60 to a day high of $4.78.
90 days $3.53 $6.05
52 weeks $3.53 $11.36

Historical Novavax Inc prices

Date Open High Low Close Volume
Mar 27, 2024 $4.73 $4.85 $4.68 $4.85 3 751 380
Mar 26, 2024 $4.89 $4.92 $4.70 $4.71 5 171 383
Mar 25, 2024 $4.68 $4.91 $4.66 $4.81 3 494 516
Mar 22, 2024 $4.69 $4.77 $4.63 $4.70 2 763 343
Mar 21, 2024 $4.86 $5.07 $4.71 $4.72 3 859 560
Mar 20, 2024 $4.95 $4.95 $4.64 $4.83 5 394 382
Mar 19, 2024 $5.07 $5.16 $4.92 $4.94 4 001 001
Mar 18, 2024 $5.24 $5.37 $5.10 $5.14 3 029 397
Mar 15, 2024 $4.97 $5.40 $4.91 $5.29 8 275 323
Mar 14, 2024 $5.20 $5.27 $4.92 $4.98 4 917 207
Mar 13, 2024 $5.05 $5.29 $4.99 $5.25 4 983 162
Mar 12, 2024 $5.16 $5.22 $4.98 $5.06 4 024 797
Mar 11, 2024 $5.45 $5.62 $5.12 $5.13 5 742 202
Mar 08, 2024 $5.68 $5.98 $5.43 $5.45 8 180 743
Mar 07, 2024 $5.67 $5.83 $5.56 $5.61 5 906 421
Mar 06, 2024 $5.65 $5.81 $5.41 $5.61 7 676 578
Mar 05, 2024 $5.37 $6.00 $5.34 $5.57 13 633 943
Mar 04, 2024 $5.44 $5.58 $5.10 $5.49 8 824 709
Mar 01, 2024 $5.09 $5.50 $4.76 $5.39 14 529 106
Feb 29, 2024 $4.40 $5.11 $4.38 $4.94 18 607 084
Feb 28, 2024 $4.64 $4.70 $4.23 $4.41 31 239 070
Feb 27, 2024 $5.61 $6.05 $5.53 $6.02 15 976 390
Feb 26, 2024 $5.41 $5.73 $5.28 $5.50 15 116 927
Feb 23, 2024 $5.06 $5.46 $4.91 $5.29 18 293 567
Feb 22, 2024 $4.46 $5.46 $4.38 $4.88 40 559 058
Click to get the best stock tips daily for free!

About Novavax Inc

Novavax Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical tria... NVAX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT